menu toggle

ISPOR 2023

AmerisourceBergen at ISPOR 2023 

Join AmerisourceBergen and global healthcare leaders as we convene in Boston at ISPOR 2023, the leading global conference for Health Economics and Outcomes Research (HEOR) on May 7-10.

Meet with us at booth #917.

Business women and men at a conference table talking

Start a conversation

Business women and men at a conference table talking
From HEOR to reimbursement strategy and field support, our consultants span a broad range of expertise to help manufacturers accelerate product success. Schedule time to meet with our experts on how to accelerate your products potential.
Business women and men at a conference table talking

ISPOR Workshop

Don't miss out on an engaging discussion at ISPOR 2023. Join Kimberly Westrich, Director, Value & Access Strategy, on Tuesday, May 9 at 10:15-11:15 AM ET, as she dives into the topic of "Addressing Heterogeneity in Comparative Economic Analysis in the Decentralized US Setting: Are We Doing Enough to Support Patient-Centered Medical Decision-Making?" Kimberly is a true expert in this field, and her insights are sure to be both valueable and engaging. Add this session to you ISPOR agenda! 


Road to commercialization in Canada

Expand into the Canadian Market

Bringing a new therapy to market can be a long and complex process. We offer full end-to-end Canadian commercialization services tailored to meet your needs. With expert knowledge in the relevant service areas and a dedicated point of contact to guide you along the way, we make the experience seamless for you. By using our integrated network of solutions, we can help you to bring your products to the Canadian market successfully so they can reach the patients who need them. 

Don't miss our poster presentations during ISPOR 2023:

We're excited to share groundbreaking research at ISPOR! Our research covers everything from the most critical challenges facing healthcare to showcasing groundbreaking solutions and the latest advancements in HEOR. We are incredibly proud to contribute to the conversation and share our findings. Don't miss out on this opportunity to join us and be a part of the discussion on addressing these critical issues. 


professionals talking with laptop

FormularyDecisions®

Discover your perfect HCDM digital engagement package 

Would you like to gain a competitive edge in engaging with healthcare decision makers (HCDMs)? Simply answer a few questions, and receive personalized recommendations straight to your inbox. With FormularyDecisions, you can impact and enhance your HCDM engagement strategy, staying ahead of the game. Don't miss out on this opportunity to unlock the full potential of digital HCDM engagement. Take our quiz today and elevate your HCDM engagement strategy to the next level!

Catch up on the latest edition of HTA Quarterly

HTA Quarterly | Summer 2023

10 years of HTA Quarterly: Looking back to see how far we’ve come

On the 10th anniversary of HTA Quarterly, the editors take a look back at some of the articles published to date, identify key themes that resonate with our readers, and consider how shifts in the constantly changing world of market access have shaped article content.
HTAQ 10 year anniversay

HTA Quarterly | Summer 2023

Project Orbis: A three-year review

Project Orbis was launched by the FDA Oncology Center of Excellence to facilitate faster patient access to innovative cancer therapies in multiple countries. Leveraging a consortium of participating countries, Project Orbis aims for concurrent submission, review, and regulatory action for high-impact, clinically significant marketing applications among participating countries. This article provides an overview of the process and recent experiences of participating regulatory agencies, highlighting the benefits and challenges for stakeholders in the 3½ years since the first regulatory decision under Project Orbis took place in September 2019.
htaq project orbis

HTA Quarterly | Summer 2023

Reflections on an interview with a ghost

Is artificial intelligence (AI) set to take over the world? In this article, we reflect on an interview we conducted with one of the current AI tools, in which we explored its “knowledge” of and potential role in health technology assessment (HTA).
HTAQ AI File 1
Xcenda_2_3_Card-02

Subscribe today

HTA Quarterly

Catch up on the latest global health technology assessment (HTA) news, gain insights from our experts around evolving HTA priorities, and browse our past issues.

 

Additional thought-leadership on HTA and global market access

Three questions to ask about your market access partner

The essential guide to drug commercialization

Why FormularyDecisions® is the right choice for enterprise biopharma payer engagement 
 

consulting servcices_top banner

Start a conversation

consulting servcices_top banner
Our consultative approach and extensive reach across healthcare give us access to the best insights in the industry- insights we leverage to help commercialization challenges for our partners and patients they serve. 
consulting servcices_top banner